BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37149843)

  • 41. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review.
    Kougioumtzi A; Ntellas P; Papadopoulou E; Nasioulas G; Kampletsas E; Pentheroudakis G
    ESMO Open; 2019; 4(5):e000561. PubMed ID: 31749991
    [No Abstract]   [Full Text] [Related]  

  • 43. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
    Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
    Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
    Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
    Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
    PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
    Lucena-Araujo AR; Moran JP; VanderLaan PA; Dias-Santagata D; Folch E; Majid A; Kent MS; Gangadharan SP; Rangachari D; Huberman MS; Kobayashi SS; Costa DB
    Lung Cancer; 2016 Sep; 99():17-22. PubMed ID: 27565908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
    Du X; Shao Y; Qin HF; Tai YH; Gao HJ
    Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Utility of Cell-Free DNA for the Detection of
    McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
    Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
    [No Abstract]   [Full Text] [Related]  

  • 53. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
    Sampson J; Richards MW; Choi J; Fry AM; Bayliss R
    EMBO Rep; 2021 Dec; 22(12):e53693. PubMed ID: 34661367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency, clinical features and differential response to therapy of concurrent
    Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
    Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
    [No Abstract]   [Full Text] [Related]  

  • 56. The biology and treatment of EML4-ALK non-small cell lung cancer.
    Sasaki T; Rodig SJ; Chirieac LR; Jänne PA
    Eur J Cancer; 2010 Jul; 46(10):1773-80. PubMed ID: 20418096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
    Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
    ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.